|
||||||||
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Select Publications
Bonneterre J et al. Anastrozole versus tamoxifen as first-line therapy for advanced
breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000;18(22):3748-57. Abstract
Buzdar AU et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: An update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 2007;13(1):228-33. Abstract
Buzdar AU et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005;23(16):3676-85. Abstract
Gradishar W et al. Fulvestrant versus exemestane following prior non-steroidal aromatase inhibitor therapy: First results from EFECT, a randomized, phase III trial in postmenopausal women with advanced breast cancer. San Antonio Breast Cancer Symposium 2006;Abstract 12.
Ingle JN et al. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J Clin Oncol 2006;24(7):1052-6. Abstract
Lonning PE et al. Activity of exemestane in metastatic breast cancer after failure of
nonsteroidal aromatase inhibitors: A phase II trial. J Clin Oncol 2000;18(11):2234-44. Abstract
Mackey JR et al. Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer. San Antonio Breast Cancer Symposium
2006;Abstract 3.
Mouridsen H et al. Phase III study of letrozole versus tamoxifen as first-line therapy
of advanced breast cancer in postmenopausal women: Analysis of survival and
update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003;21(11):2101-9. Abstract
Nabholtz JM et al. Anastrozole is superior to tamoxifen as first-line therapy for
advanced breast cancer in postmenopausal women: Results of a North American
multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000;18(22):3758-67. Abstract
 |
 |
